To see if subtypes of breast cancer were predicted to show differential sensitivity to any of the 270 drugs, we divided the ~ 1100 TCGA BRCA samples into five subgroups (basal-like, Her2-positive, luminal A, luminal B, and normal-like) based on the PAM50 classification [53, 54]. This evidence concerns the gene ERBB2 and breast carcinoma.